The first reimbursed immunotherapy option has been introduced to the field of endometrial cancer in Korea.

According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has been listed for reimbursement in Korea from December 1st.

Since receiving marketing authorization from the Ministry of Food and Drug Safety in December last year, the company moved relatively quickly through the reimbursement process, passing HIRA’s Drug Reimbursement Evaluation Committee deliberation in August, and recently completed drug price negotiations with the NHIS and received approval from the Health Insurance Policy Review Committee.

GSK has been carrying out an Expanded A